Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial

Grant, Jon E.; Kim, Suck Won; Potenza, Marc N.; Blanco, Carlos; Ibanez, Angela; Stevens, Lee; Hektner, Joel M.; Zaninelli, Rocco

International Clinical Psychopharmacology: July 2003 - Volume 18 - Issue 4 - p 243–249
ORIGINAL ARTICLES
Buy

Previous studies have suggested the efficacy of serotonergic agents in the treatment of pathological gambling. The aim of the present study was to determine whether treatment with paroxetine in a large sample of subjects with pathological gambling would effectively diminish the severity of gambling symptoms. A 16-week, double-blind, placebo-controlled trial was conducted at five outpatient academic research centres in two countries (USA and Spain). Seventy-six outpatients (mean age 45.4±10.6 years; 30 women, 46 men) with pathological gambling were randomized to acute treatment with paroxetine in flexible daily dosages of 10–60 mg/day (n=36) or placebo (n=40). The primary outcome measure was the Clinical Global Impressions scale. Both the paroxetine- and the placebo-treated groups demonstrated comparable improvement at 16 weeks (59% response rate in the paroxetine group, 49% rate in the placebo group; chi squared=0.737; d.f.=1;P=0.390). Paroxetine consistently resulted in a greater percentage of responders at each study visit compared to placebo but failed to demonstrate statistical superiority to placebo on scores on the Clinical Global Impressions scale, the Yale–Brown Obsessive–Compulsive Scale Modified for Pathological Gambling, or the Gambling Symptom Assessment Scale. High rates of symptom improvement were observed in pathological gamblers receiving either paroxetine or placebo after 16 weeks. Paroxetine consistently demonstrated an advantage over placebo on the Clinical Global Impressions scale; however, a larger sample size may have registered significant differences.

a Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota, USA

b Department of Psychiatry, Yale University, New Haven, Connecticut, USA

c Department of Psychiatry, Columbia University, New York, New York, USA

d Department of Psychiatry, Ramon y Cajal Hospital, University of Alcala, Madrid, Spain

e Louisiana State University, Health Sciences Centre, Shreveport, Louisiana, USA

f North Dakota State University, Fargo, North Dakota, USA

g 200 West 60th Street, New York, New York, USA

Correspondence and requests for reprints to Jon E. Grant, Department of Psychiatry, University of Minnesota Medical School, 2450 Riverside Avenue, Minneapolis, MN 55454-1495, USA.

Tel: +1 612 627 4879: fax: +1 612 627 4878: e-mail: grant045@umn.edu

Received 4 February 2003 Accepted 20 March 2002

Copyright © 2003 Wolters Kluwer Health, Inc. All rights reserved.